Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | EML4 | Q9HC35 | 15/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 15/20 | 0.34 |
| ▸ | RET | P07949 | 8/20 | 0.32 |
| ▸ | ROS1 | P08922 | 8/20 | 0.32 |
| ▸ | FLT3 | P36888 | 8/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205534 | 0.89 | MTOR (0.41) | AXLEML4ALKRETROS1 | |
| SCHEMBL24944748 | 0.89 | MTOR (0.41) | AXLEML4ALKRETROS1 | |
| SCHEMBL30205512 | 0.89 | MTOR (0.41) | AXLEML4ALKRETROS1 | |
| SCHEMBL24944438 | 0.89 | MTOR (0.41) | AXLEML4ALKRETROS1 | |
| SCHEMBL30801947 | 0.86 | JAK1 (0.33) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944764 | 0.85 | LRRK2 (0.34) | EML4ALKRETROS1FLT3 | |
| SCHEMBL30205545 | 0.85 | LRRK2 (0.34) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944436 | 0.84 | EML4 (0.36) | AXLEML4ALKRETROS1 | |
| SCHEMBL30205483 | 0.84 | EML4 (0.36) | AXLEML4ALKRETROS1 | |
| Formic Acid SCHEMBL30206327 | 0.84 | BTK (0.32) | EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |